Early and Long-Term Responses to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data

American Journal of Ophthalmology

Volumn 172, Issue , 2016, Pages 72-79

  Gonzalez, Victor H ^a   Campbell, Joanna ^b   Holekamp, Nancy M ^c   Kiss, Szilárd ^d   Loewenstein, Anat ^e   Augustin, Albert J ^f   Ma, Julia ^b   Ho, Allen C ^g   Patel, Vaishali ^b   Whitcup, Scott M ^h   Dugel, Pravin U ^i,j  

^a Valley Retina Institute   (United States)

^b ALLERGAN INC   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e TEL AVIV UNIVERSITY   (Israel)

^f STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^g WILLS EYE HOSPITAL   (United States)

^h JULES STEIN EYE INSTITUTE   (United States)

ⁱ RETINAL CONSULTANTS OF ARIZONA   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; TRIAMCINOLONE; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; BEST CORRECTED VISUAL ACUITY; CHRONOPHARMACOLOGY; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; FEMALE; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84994588602     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2016.09.012     Document Type: Article

References (22)

1. 1 Mitchell, P., Bandello, F., Schmidt-Erfurth, U., et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:4 (2011), 615–625.
2. 2 Massin, P., Bandello, F., Garweg, J.G., et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:11 (2010), 2399–2405.
3. 3 Diabetic Retinopathy Clinical Research Network, Elman, M.J., Aiello, L.P., Beck, R.W., et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:6 (2010), 1064–1077.
4. 4 Michaelides, M., Kaines, A., Hamilton, R.D., et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 117:6 (2010), 1078–1086.
5. 5 Korobelnik, J.F., Do, D.V., Schmidt-Erfurth, U., et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:11 (2014), 2247–2254.
6. 6 Do, D.V., Nguyen, Q.D., Boyer, D., et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119:8 (2012), 1658–1665.
7. 7 Elman, M.J., Bressler, N.M., Qin, H., et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118:4 (2011), 609–614.
8. 8 Rajendram, R., Fraser-Bell, S., Kaines, A., et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130:8 (2012), 972–979.
9. 9 Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:4 (2012), 789–801.
10. 10 Elman, M.J., Qin, H., Aiello, L.P., et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 119:11 (2012), 2312–2318.
11. 11 Elman, M.J., Ayala, A., Bressler, N.M., et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122:2 (2015), 375–381.
12. 12 Kriechbaum, K., Prager, S., Mylonas, G., et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye (Lond) 28:1 (2014), 9–15.
13. 13 Rezaei KA, Stone TW. American Society of Retina Specialists (ASRS): Global trends in retina survey 2014. Available at: https://www.asrs.org/content/documents/2014_global_trends_comprehensivepostmtg.pdf. Accessed October 24, 2016.
14. 14 Bressler, S.B., Qin, H., Beck, R.W., et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 130:9 (2012), 1153–1161.
15. 15 Sophie, R., Lu, N., Campochiaro, P.A., Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology 122:7 (2015), 1395–1401.
16. 16 Wallick, C.J., Hansen, R.N., Campbell, J., Kiss, S., Kowalski, J.W., Sullivan, S.D., Comorbidity and health care resource use among commercially insured non-elderly patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina 46:7 (2015), 744–751.
17. 17 Kiss, S., Liu, Y., Brown, J., et al. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol 8 (2014), 1611–1621.
18. 18 Campbell, J., Cole, A.L., Almony, A., et al. Real world vision outcomes in DME treated with anti-VEGF injections: an analysis of EMR data from a large health system. Invest Ophthalmol Vis Sci, 55(13), 2014, Abst 3065.
19. 19 Fong, D.S., Luong, T., Contreras, R., et al. Two year visual acuity outcomes in clinical practice of diabetic macular edema treated with anti-VEGF therapy in an integrated US healthcare system. Invest Ophthalmol Vis Sci, 56(7), 2015 Abst 1418.
20. 20 Agarwal, A., Soliman, M.K., Sepah, Y.J., Do, D.V., Nguyen, Q.D., Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics. Pharmgenomics Pers Med 7 (2014), 399–409.
21. 21 El-Shazly, S.F., El-Bradey, M.H., Tameesh, M.K., Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes. Clin Experiment Ophthalmol 42:4 (2014), 369–378.
22. 22 Matsuda, S., Tam, T., Singh, R.P., et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications 28:2 (2014), 166–170.